Shares of Moderna rose sharply Thursday after the vaccine company reported better-than-expected quarterly results and ...

MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.

Moderna (MRNA) stock gains as the company beats Q3 2025 forecasts despite lower COVID vaccine sales and narrows revenue ...

Moderna stock is trading sharply lower Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.

Biotechnology company Moderna (NASDAQ:MRNA) in Q3 CY2025, but sales fell by 45.4% year on year to $1.02 billion. On the other ...

Mixed earnings results were being mentioned on Thursday as possible catalysts behind Thursday's stock-market action. Shares of Moderna Inc. were up more than 3% after the vaccine maker reported a ...

Moderna (NASDAQ:MRNA) stock surged as much as 12% Thursday following a STAT News report that the COVID-19 vaccine maker has been in discussions with at least one large pharmaceutical company about "a ...

Moderna's shares have been southbound for the past few years due to unimpressive financial results. However, progress with the pipeline could significantly boost the stock over the next five years.

Qualcomm (NASDAQ:QCOM) stock dropped 1.4% as fears the chip designer will lose business from Samsung, a key customer, ...

Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the ...

Get the latest on Moderna’s Q3 earnings, analyst forecasts, COVID-19 vaccine sales impact, and what could shape MRNA’s stock ...

Investing.com - Moderna (NASDAQ: MRNA) reported third quarter EPS of $-0.51, $1.54 better than the analyst estimate of $-2.05. Revenue for the quarter came in at $1.02B versus the consensus estimate ...